Having trouble accessing articles? Reset your cache.

G-BA issues final assessments for Inlyta, aclidinium bromide

Germany's Federal Joint Committee (G-BA) said Inlyta axitinib from Pfizer Inc. (NYSE:PFE) provides a "marginal" additional benefit over requested comparator Nexavar sorafenib to treat advanced renal cell

Read the full 275 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE